Covance partners on Japan trial lab; are preclinical cuts ahead?
Covance has set up a central trial laboratory on Kawagoe City, Japan in partnership with local testing firm BML.
BBK and CROee partner to boost recruitment in Japan
BBK Worldwide and CROee take on Japan’s notorious “drug lag” with new partnership offering faster patient recruitment and trial site identification.
Quintiles relocates Japan lab in response to “huge growth”
Quintiles has relocated its global central laboratory in Japan to meet rising demand from the local market and US and European pharmas keen to include the country in their clinical trial network.
BKK sets up in Japan to combat recruitment lag
US Patient recruitment specialist BBK Worldwide has set up a unit in Osaka, Japan to improve enrolment rates for studies in the country and help local pharma and biotech firms cut costs.
CBI plants presence in Japan
Commonwealth Biotechnologies (CBI) has planted its first roots in
Japan, as the world's number two pharmaceutical market continues to
attract foreign firms.
Japan's contract manufacturing awakening
2005 marked the real beginning of contract manufacturing in Japan,
which had been held back by an overly-cautious regulatory
environment and significant and unique quality and specification
demands in the marketplace.
BioReliance establishes in Asia Pacific
BioReliance has established itself in the Asia Pacific with the
opening of its first office in the region, in Tokyo, Japan.
Pfizer offers insight on R&D outsourcing in Japan
Pfizer, among others, recently offered an insight into R&D
outsourcing in Japan, where this services market is still fairly
immature, with growth potential in several key areas.
Asia becoming important Phase I player
Phase I development in Asia is becoming very important, delegates
heard at the recent Drug Information Association (DIA) meeting in
'Developing' Japan intent on clinical trial catch-up
Japan is getting serious about clinical trial reform after years of
lagging behind the rest of the developed world in the availability
of drugs in the country, which ironically is the world's number two
pharma market behind the...
Japan picking up on manufacturing outsourcing trend
Japan's market for contract manufacturing activities is predicted
to double by 2009 as the outsourcing trend begins to take off in
Proditec provides affordable tablet inspection
Proditec exhibited its new automatic visual tablet inspection
system at the recent CPhI, designed to provide the first
alternative to manual pharmaceutical tablet inspection for smaller
Chugai rejigs manufacturing with plant closures
Japan's Chugai Pharmaceutical is planning to slash the number of
manufacturing plants it operates in Japan in the wake of its
alliance with Switzerland's Roche in 2002.
DiscoveRx and B-Bridge enters Japanese territory
DiscoveRx and B-Bridge International are to venture into the
Japanese assay market that aims to provide Japanese researchers
with a homogenous GPCR and Kinase assay platform for drug
development and screening.
Artificial tongue helps medicine go down
Japan's Insent has developed an artificial tongue - said to be the
first of its kind - that can be used to analyse the taste profiles
of pharmaceuticals, foods and beverages.
Capital investments by pharma players
Companies from Europe, the US and Japan have announced the
construction of new facilities this month, suggesting that despite
a difficult operating environment big pharma is still making
significant capital investments.
Avecia strengthens Japanese operations
Avecia Pharmaceuticals has consolidated its position in the
evolving Japanese pharmaceutical market by forging a technology
agreement with a local company,reports Phil Taylor.
EFPIA calls for change in Japan
Japan is losing out competitively at the expense of its rivals in
the global pharmaceutical industry, says EFPIA, and must take steps
to improve the environment for drug companies.
Kyorin unveils new oral dose plant
Japan's Kyorin Pharmaceuticals plans to invest some 8 billion yen
(€62.5m) in a new facility to produce tablet and capsule
Funguard capacity to swell on sales growth
Fujisawa has decided to build a new formulation plant for its
recently launched antifungal Funguard with a capital investment of
Y3.8 billion (€28m).
Eisai invests in manufacturing capacity
Japanese drugmaker Eisai is planning to double the production
capacity for its two top-selling drugs - Pariet and Aricept - by
2004, with an investment of ¥9 billion (€65m).